

How To Prevent And Manage Peri-procedural Aortic Regurgitation

Gerald Yong MBBS (Hons) FRACP FSCAI Interventional Cardiologist Royal Perth Hospital Western Australia

TCTAP 24 April 2013

Disclosure Statement of Financial Interest

Within the past 12 months, I or my spouse/partner have had a financial Interest /arrangement or affiliation with the organization(s) listed below

<u>Affiliation/Financial Relationship</u> Grant/ Research Support:

Consulting Fees/Honoraria:

Major Stock Shareholder/Equity Interest: Royalty Income:

Ownership/Founder:

Salary:

Intellectual Property Rights:

Other Financial Benefit:

Company


Edwards Lifesciences (consultant & proctor)

Paravalvular Leak After Transcatheter Aortic Valve Replacement


The New Achilles' Heel? A Comprehensive Review of

Philippe Généreux, MD,*†‡ Stuart J. Head, MSC,§ Rebecca Hahn, M Susheel Kodali, MD,*† Mathew R. Williams, MD,*† Nicolas M. van I Maria C. Alu, MM,* Patrick W. Serruys, MD, PHD, A. Pieter Kapp Martin B. Leon, MD*†

New York, New York; Montréal, Québec, Canada; and Rotterdam, the Ne



PARTNER COHORT A - Aortic Regurgitation (As Treated)




Kodali, S. K., et al. N Engl J Med. 2012;366:1686-95

ORIGINAL ARTICLE

Two-Year Outcomes after Transcatheter or Surgical Aortic-Valve Replacement

B Severity of Paravalvular Leak: None or Trace, Mild, or Moderate to Severe



Kodali, et al., NEJM, 2012;366:1686-95

Incidence, Predictors, and Outcomes of Aortic Regurgitation After Transcatheter Aortic Valve Replacement

Meta-Analysis and Systematic Review of Literature

Ganesh Athappan, MD,*† Eshan Patvardhan, MD,* E. Murat Tuzcu, MD,* Lars Georg Svensson, MD, PHD,‡ Pedro A. Lemos, MD,§ Chiara Fraccaro, MD, PHD, Giuseppe Tarantini, MD, PHD, Jan-Malte Sinning, MD, Georg Nickenig, MD,¶ Davide Capodanno, MD, PHD,# Corrado Tamburino, MD, PHD,# Azeem Latib, MD,** Antonio Colombo, MD,** Samir R. Kapadia, MD* *Cleveland, Ohio; São Paulo, Brazil; Padova, Catania, and Milan, Italy; and Bonn, Germany*

Meta-analysis of 45 studies between 2002-2012
Edwards 7,279; CoreValve 5,261

Incidence of moderate or severe PVL - 13.9%

- Edwards 9.1%
- CoreValve 16.0%


Paravalvular Regurgication Impacts on Mortality...

Study name	Statistics for each study				Hazard ratio and 95% C					% CI		
	Hazard ratio	Lower limit	Upper limit	Z-Value	p-Value							
Lemos•	4.900	1.367	17.570	2.439	0.015	1	1	1		+	+	-;
Hayashida	1.970	1.187	3.271	2.621	0.009				1-		-	- 1
Amabile	1.500	0.329	6.829	0.524	0.600			+	+		\rightarrow	•
Sinning	3.890	2.020	7.491	4.063	0.000					\vdash	╺┼╸	-
Tamburino	3.785	1.572	9.112	2.969	0.003					+	-	-1
Fraccaro	2.190	1.023	4.686	2.020	0.043				\vdash		_	
Kodali	2.110	1.433	3.107	3.783	0.000						·	
Moat	1.490	1.002	2.215	1.971	0.049				н	∎		
Gilard	2.490	1.909	3.248	6.728	0.000						-	
All (N=4791)	2.273	1.840	2.808	7.609	0.000					+		1
						0.1	0.2	0.5 ased R	1	2	5 ased R	

Figure 4

Forest Plot Showing the HRs of Moderate or Severe AR on Overall Mortality

Study name	Statistics for each study						Hazard ratio and 95% CI								
	Hazard ratio	Lower	Upper limit	Z-Value	p-Value										
Lemos	10.080	1.229	82.673	2.152	0.031		1	1	1-	+	+				
Sinning	2.342	1.066	5.145	2.119	0.034				I-	╼	-				
Kodali	2.110	1.433	3.107	3.782	0.000				1	-					
Fraccaro	2.064	0.968	4.400	1.876	0.061				+	-	-1				
Tamburino	0.780	0.499	1.218	-1.092	0.275			⊢	+						
All (N=1620)	1.829	1.005	3.329	1.975	0.048	0,1	0.2	0.5	1	2	5				



Predictors of Paravalvular Regurgitation


Severe calcification – Agaston calcium score on CT

Low implantation depth

Markers of valve undersizing

- Small cover index
- Large annulus
- "Prosthesis / annulus mismatch"

Preventing Para-Valvular AR



Adapted from Thierry Lefevre; London Valves, 2012

Multimodality Imaging with 3D TEE or MSCT important in sizing

CLINICAL RESEARCH

Interventional Cardiology

Aortic Aortic

Imaging in Transcatheter Aortic Valve Replacement

Hasan Jilaił Asim Rafiq James Miro Kazuaki Ok Swaminatha Takahiro Sl *Los Angeles*,

3-Dime

Hasan Jilaiha Azusa Furuge Niraj Doctor, *Los Angeles*, O

Cross-Sectional Computed Tonographic AccessmentImprove3-Dimensional Aortic Annular Assessment byTranscatMultidetector Computed Tomography Predictsthe InciModerate or Severe Paravalvular RegurgitationHasan JilaiharAfter Transcatheter Aortic Valve Replacement

A Multicenter Retrospective Analysis

Alexander B. Willson, MBBS, MPH,* John G. Webb, MD,* Troy M. LaBounty, MD,†
Stephan Achenbach, MD,‡ Robert Moss, MBBS,* Miriam Wheeler, MBBS,*
Christopher Thompson, MD,* James K. Min, MD,† Ronen Gurvitch, MBBS,* Bjarne L. Norgaard, MD,§
Cameron J. Hague, MD,* Stefan Toggweiler, MD,* Ronald Binder, MD,* Melanie Freeman, MBBS,*
Rohan Poulter, MBBS,* Steen Poulsen, MD,§ David A. Wood, MD,* Jonathon Leipsic, MD*
Vancouver, Canada; Los Angeles, California; Giessen, Germany; and Aarhus, Denmark

Possible Mechanisms of Severe Regurgitation Post-TAVR

Central valvular regurgitation

Low deployment

Inadequate apposition
Calcium
Underzing

Assessment

Confirm severity of aortic regurgitation Echo – TEE Aortography Hemodynamics – AR index Assess valvular vs paravalvular ■ TEE Assess position of implantation ■ TEE Aortography

Immediate Treatment of Severe Aortic Regurgitation During TAVR

- Pace faster \rightarrow reduce diastole

Pressor support

Mechanical support likely not helpful

Urgency to institute definitive Rx

- New valve
- Post-dilate
- Conversion to surgery

Central valvular regurgitation

Low deployment

Inadequate apposition to leaflets / annulus due to severe valvular calcification +/- inadequate balloon dilatation


Central Valvular Regurgitation

Frozen leaflets, overhanging leaflets

Can attempt to loosen leaflet with diagnostic coronary catheter

Prepare and replace valve with another valve as valve-in-valve bailout

Frozen Leaflets due to Low Implantation




Toggweiler et al. J Am Coll Cardiol Intv 2012;5:571-7

Possible Mechanisms of Severe Regurgitation Post-TAVI


- Central valvular regurgitation
- Low deployment

Inadequate apposition to leaflets / annulus due to severe valvular calcification +/- inadequate balloon dilatation













LOW POSITION




Valve dived ventricular!!









Severe PVL due to Low Positioning










Transcatheter Valve-In-Valve Implantation for Failed Balloon-Expandable Transcatheter Aortic Valves

Stefan Toggweiler, MD,* David A. Wood, MD,* Josep Rodés-Cabau, MD,† Samir Kapadia, MD,‡ Alexander B. Willson, MBBS, MPH,* Jian Ye, MD,* Anson Cheung, MD,* Jonathon Leipsic, MD,* Ronald K. Binder, MD,* Ronen Gurvitch, MBBS,* Melanie Freeman, MBBS,* Christopher R. Thompson, MD,* Lars G. Svensson, MD,‡ Eric Dumont, MD,† E. Murat Tuzcu, MD,‡ John G. Webb, MD*

Vancouver, British Columbia, and Quebec City, Quebec, Canada; and Cleveland, Ohio

- 760 consecutive TAVR in 3 centers with balloon expandable valve
- THV-in-THV performed in 21 cases due to severe AR (2.8%)
- Reasons:
 - Malposition: 10 too aortic, 8 too ventricular
 - Valvular regurgitation: 3
- Technically successful in 19 patients
 - Unsuccessful in 2 patients due to ventricular embolization in both cases
- PPM 2/21 (9.5%) (vs. 6% in conventional TAVR; p=NS))
- Stroke 1/21 (4.7%) (vs. 2% in conventional TAVR; p=NS)

Toggweiler et al. J Am Coll Cardiol Intv 2012;5:571–7




Toggweiler et al. J Am Coll Cardiol Intv 2012;5:571-7

The Valve-in-Valve Technique for Treatment of Aortic Bioprosthesis Malposition

An Analysis of Incidence and 1-Year Clinical Outcomes From the Italian CoreValve Registry

Gian Paolo Ussia, MD,*† Marco Barbanti, MD,* Angelo Ramondo, MD,‡ Anna Sonia Petronio, MD,§ Federica Ettori, MD,|| Gennaro Santoro, MD,¶ Silvio Klugmann, MD,# Francesco Bedogni, MD,** Francesco Maisano, MD,†† Antonio Marzocchi, MD,‡‡ Arnaldo Poli, MD,§§ Massimo Napodano, MD,‡ Corrado Tamburino, MD, PHD*† *Catania, Padova, Pisa, Brescia, Florence, Milano, Bologna, and Legnano, Italy*

- 663 consecutives TAVR in 14 centers in Italy with CoreValve
- Valve-in-Valve rescue performed in 24 pts (3.6%)
- All successful technically
- No Coronary impairment
- Post-dilatation 50% (vs. 8.8% in conventional TAVR; p<0.001)</p>
- PPM 33.3% (vs 14.5% in conventional TAVR; p=0.02)
- Stroke 0 (vs. 1.2% in conventional TAVR; p=NS)



Event rates were calculated with the use of Kaplan-Meier methods and were compared with the use of the log-rank test. ViV = valve-in-valve.




Figure 4 Time-to-Event Curves for MACCE

Event rates were calculated with the use of Kaplan-Meier methods and were compared with the use of the log-rank test. MACCE = major adverse cardiovascular and cerebrovascular events; ViV = valve-in-valve.

Ussia et al. J Am Coll Cardiol 2011;57:1062-8


Possible Mechanisms of Severe Regurgitation Post-TAVI


Central valvular regurgitation

Low deployment


Inadequate apposition to leaflets / annulus due to severe valvular calcification +/- inadequate balloon dilatation

Severe PVL post Edwards THV






Severe Ca on non-coronary cusp and posterior annulus




Post-dilate – 26mm deployment balloon



Final Result

Image size: 512 x 512





Post-Dilatation – Potential Complications

Annular injury

Valve embolisation


Stroke

Conduction system disturbance and PPM

Efficacy and Safety of Postdilatation to Reduce Paravalvular Regurgitation During Balloon-Expandable Transcatheter Aortic Valve Replacement

Benoit Daneault, MD; Elana Koss, MD; Rebecca T. Hahn, MD; Susheel Kodali, MD;
 Mathew R. Williams, MD; Philippe Généreux, MD; Jean-Michel Paradis, MD; Isaac George, MD;
 George R. Reiss, MD; Jeffrey W. Moses, MD; Craig R. Smith, MD; Martin B. Leon, MD

- 258 consecutive TAVR patients with balloon expandable valve in single centre
- Post-dilatation systematically performed if paravalvular regurgication \geq 2+ in 106 patients (41%)
- Same balloon as valve-deployment used
 - Between 0-2ml additional contrast added. Most common 1ml (86%)
- Post-dilatation patients
 - Larger annulus (on echo) 23.2mm vs 21.9mm (p=0.009)
 - Lower cover index 6.9% vs 10.1% (p=0.02)



Daneault, B., et al. Circ Cardiovasc Interv. 2013;6:85-91

30-day Clinical Outcomes Post-dilatation vs No Post-dilatation

Table 3.	Clinical	Outcomes
----------	----------	----------

	Postdilatation (n=106)	No Postdilatation (n=153)	OR (95% CI)	<i>P</i> Value
30-day mortality	2 (1.9%)	11 (7.2%)	0.25 (0.05-1.14)	0.06
30-day cardiac mortality	1 (0.9%)	6 (3.9%)	0.23 (0.03–1.97)	0.25
In-hospital cerebrovascular events				
All stroke or TIA	5 (4.7%)	2 (1.3%)	3.74 (0.71–19.64)	0.13
All stroke	4 (3.8%)	1 (0.7%)	5.96 (0.66-54.10)	0.16
Aortic dissection	1 (0.9%)	1 (0.7%)	1.45 (0.09-23.4)	1.00
Aortic wall hematoma	1 (0.9%)	3 (2.0%)	0.48 (0.05-4.64)	0.65
PPM implantation during index hospitalization	6 (5.7%)	13 (8.5%)	0.65 (0.24–1.76)	0.39

Daneault, B., et al. Circ Cardiovasc Interv. 2013;6:85-91

Conclusion

 Paravalvular regurgitation is common after TAVR

 Aortic regurgitation post-TAVR impacts on clinical outcomes

Main method of avoidance
Avoid undersizing
Deploy at appropriate level

Conclusion

- Central valvular regurgitation
 - Rx Deploy 2nd valve within first valve (Valve-in-valve)
- Low deployment
 - Rx Attempt to retract valve CoreValve
 - Rx Valve in valve
- Inadequate apposition to leaflets / annulus due to severe valvular calcification +/- inadequate balloon dilatation
 - Post-dilate
 - Para-valvular plugs

Emerging devices with reduced rate of PVL




Figure 5 Emerging TAVR Devices Involving Improved Technologies, Potentially Minimizing PVL After TAVR

(A) SAPIEN 3 (Edwards Lifesciences, Irvine, California). (B) CENTERA (Edwards Lifesciences). (C) Direct Flow Medical (Direct Flow Medical, Santa Rosa, California).
 (D) Portico (St. Jude Medical, St. Paul, Minnesota). (E) Engager (Medtronic, Minneapolis, Minnesota). (F) Heart Leaflet Technologies (Heart Leaflet Technologies, Maple Grove, Minnesota). (G) JenaValve (JenaValve Technology, Munich, Germany). (H) Sadra Lotus Medical (Boston Scientific SciMed Inc., Maple Grove, Minnesota).

Généreux et al. J Am Coll Cardiol 2013

THE IMPACT OF INTEGRATION OF A COMPUTED TOMOGRAPHY ANNULUS AREA SIZING ALGORITHM ON CLINICAL OUTCOMES OF TRANSCATHETER AORTIC VALVE REPLACEMENT: A PROSPECTIVE, MULTICENTER, CONTROLLED TRIAL

Oral Contributions West, Room 2010 Sunday, March 10, 2013, 11:45 a.m.-Noon

Session Title: Valvular Heart Disease: Prognostic Features and Technical Advances to Optimize TAVR Outcomes Abstract Category: 32. Valvular Heart Disease: Therapy Presentation Number: 931-7

Authors: <u>Ronald K. Binder</u>, John Webb, Marina Urena, Nicolaj Hansson, Josep Rodes-Cabau, Bjarne L. Norgaard, Philippe Pibarot, Marco Barbanti, Eric Larose, Melanie Freeman, Eric Dumont, Christopher Thompson, Sergio Pasian, Giang Nguyen, Rekha Raju, Stefan Toggweiler, Alexander B. Willson, David Wood, Jonathon Leipsic, St. Paul's Hospital - University of British Columbia, Vancouver, Canada, Quebec Heart and Lung Institute, Laval University, Quebec, Canada

Background: Appreciation of the complex non-circular geometry of the aortic annulus by three-dimensional imaging is important for accurate transcatheter heart valve (THV) size selection. We prospectively investigated the impact of integration of a multidetector computed tomography (MDCT) annular area sizing algorithm on transcatheter aortic valve replacement (TAVR) outcomes.

Methods: Patients planned for TAVR in four high-volume, experienced centers underwent pre-procedural MDCT. Recommendations for THV size were based on a MDCT sizing algorithm with an optimal goal of modest annulus area over sizing (5 % - 10 %). Consecutive patients, who underwent TAVR with the implementation of the algorithm (MDCT group), were compared to consecutive patients, who underwent TAVR without the algorithm (control group, CG) prior to trial initiation. Primary endpoint was the incidence of more than mild paravalvular regurgitation (PAR) and the secondary endpoint was the composite of in-hospital death, aortic annular rupture, THV-in-THV implantation and THV embolization.

Results: Of 324 patients, in the trial, 108 patients underwent TAVR (SAPIEN XT THV) with the implementation of the MDCT sizing algorithm (MDCT group) and 216 patients without the algorithm (CG). Post procedural aortic valve area was 1.6 ± 0.3 cm2 in the MDCT group and 1.6 ± 0.4 cm2 in the CG (p = 0.578). Moderate or severe PAR was apparent in 3.7 % (4/108) in the MDCT group and 10.2 % (22/216) in the CG (p = 0.043). The combined secondary endpoint occurred in 2.8 % in the MDCT group and in 9.3 % in the CG (p = 0.032). There were 3 (2.8 %) in-hospital deaths in the MDCT group and 12 (5.6 %) in the CG (p = 0.262). The rates of annular rupture were 0.9 % vs 1.4 % (p = 0.722), THV-in-THV implantation 0 % vs 1.9 % (p = 0.155) and THV embolization 0 % vs 3.2 % (p = 0.059) in the MDCT group vs CG respectively.

Conclusion: In this prospective, multicenter, controlled trial the implementation of a MDCT annulus area sizing algorithm for TAVR significantly reduced PAR and the combined endpoint of in-hospital death, annular rupture, THV-in-THV implantation and THV embolization. Three-dimensional aortic annular assessment and annular area sizing by MDCT should be recommended for TAVR.